Life at Zymeworks


Zymeworks to Present Trials in Progress Poster for HERIZON-GEA-01 at ESMO GI

Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results

Zymeworks Announces Participation In Upcoming Investor Conferences

Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer

Zymeworks Announces Presentations At 2022 American Society Of Clinical Oncology (ASCO) Annual Meeting

Zymeworks To Host First Quarter 2022 Results Conference Call

Zymeworks Announces Participation In Upcoming Investor Conferences

Zymeworks Announces Participation In Upcoming Investor Conferences

Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results

Zymeworks To Host Fourth Quarter And Full Year 2021 Results Conference Call

Zymeworks Provides Corporate Update On Key Strategic Priorities And Outlook For 2022

Zymeworks To Present At 40th Annual J.P. Morgan Healthcare Conference

Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani

Zymeworks Announces Second Janssen Bispecific Antibody To Begin Clinical Development Utilizing Azymetric™ And EFECT™ Therapeutic Platforms

Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)

Mediacorp Recognizes Zymeworks as One of Canada’s 2022 Top 100 Employers

Zymeworks Launches Global Phase 3 Zanidatamab Trial In First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)

Zymeworks-GSK Collaboration Leads To Design and Validation of a Novel Engineered, FcγRIIb-Selective Fc Platform for Therapeutic Antibody Development

November is Stomach Cancer Awareness Month

Zymeworks Shares Perspective on the Promise of Multi-Specific Antibodies at Digital STAT News Event

Zymeworks Announces Webcast To Present HERIZON-GEA-01 Pivotal Trial Design And Zanidatamab Commercial Strategy In Gastrointestinal Cancers

Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors

Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate And Durability In First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) At The European Society For Medical Oncology (ESMO) Annual Congress

Cholangiocarcinoma Foundation (CCF) Launches Program to Support Newly Diagnosed Patients and Their Caregivers

Great Place to Work Canada Names Zymeworks Among 2021 Best Workplaces™ In Healthcare

Zymeworks Announces Abstract For Zanidatamab In First-Line HER2-Expressing Gastroesophageal Cancers (GEA) At The European Society For Medical Oncology (ESMO) Annual Congress

Zymeworks Recognized Among Canada’s 2021 Best Workplaces™ for Giving Back

Zymeworks Reports 2021 Second Quarter Financial Results

Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric™ and EFECT™ Therapeutic Platforms

Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy

Zymeworks Team Carries the Journey of Hope Torch to Hope, Canada

Zymeworks Supports Dave’s 15,000 Mile Journey of Hope

Zymeworks to Present at Jefferies Virtual Healthcare Conference

Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

FDA Clears Zanidatamab Phase 3 Pivotal Trial in First Line HER2-positive Gastroesophageal Adenocarcinoma

Zymeworks Reports 2021 First Quarter Financial Results

Zymeworks to Present at Bloom Burton Healthcare Conference

Zymeworks Introduces Fourth Therapeutic Platform, ProTECT™

Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting

Congratulations to Zymeworks Scientist Anna von Rossum, Healthcare Business Women’s Association 2021 Rising Star!

Zymeworks is Proud of Two National Top Employer Recognitions Received in Canada, and Even Prouder of Our People Who Make Zymeworks Such a Great Place to Work!